Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet)

Fundacion Sales

Dana-Farber-Cancer Institute Inc.

The Brigham and Women's Hospital, Inc.

Inis Biotech LLC

Conicet

Funadción Sales

Gabriel Rabinovich

Margaret A Shipp

Jeffery L Kutok

Scott J Rodig

Jing Ouyang

Mariana Salatino

Diego Omar Croci Russo

Kunihiko Takeyama

Juan Pablo Cerliani

Przemyslaw Juszczynski

Pablo Francisco Hockl

Nicolás Alejandro Pinto

Juan Manuel Pérez Sáez

The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and method for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.

Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1

A method for modulating angiogenesis in a cancer or tumor refractory to anti-VEGF, including identifying a cancer cell as being referactory to anti-VEGF, and then contacting the cancer cell refractory to anti-VEGF with an effective amount of an agent that modulates interaction between Gal1 or a Gal1 fragment and the natural binding partner of Gal1 or the Gal1 fragment to thereby modulate angiogenesis.

Methods for modulating angiogenesis of cancers refractory to anti-VEGF treatment

Compositions, kits, and methods for the diagnosis prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1

This invention provides methods of modulating immune responses in the skin. The invention further provides methods of treatment for psoriasis, epidermal and dermal inflammation, and associated dermal immunity conditions by administering to an individual patient in need an effective amount of Gal-7, functional fragments of Gal-7, or agonists of Gal-7.

Therapeutic modulation of skin immune system with Gal-7

The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma, anaplastic large cell lymphoma, or MLLpre B-cell ALL. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, and monitoring immune disorders, e.g., Hodgkin lymphoma, anaplastic large cell lymphoma, or MLLpre B-cell ALL.

Compositions, kits, and methods for the diagnosis, prognosis, and monitoring of immune disorders using galectin-1

The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma. Accordingly, the invention relates to compositions, kits, and methods for detecting, characterizing, modulating, preventing, and treating immune disorders, e.g., Hodgkin lymphoma.

Compositions, kits, and methods for the modulation of immune responses using galectin-1

The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.

Growing community of inventors

Ciudad de Buenos Aires, Argentina

Gabriel Rabinovich